Loading
Life sciences · Journal article
International Journal of Molecular Sciences · September 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
A high-fat diet is associated with metabolic disorder, including obesity, insulin resistance, dyslipidemia, and hypertension. Polysaccharides derived from mushrooms have attracted interest for their potential metabolic and anti-inflammatory effects. Nevertheless, the impact of crude polysaccharides derived from the Lentinula edodes (Berk.) Pegler PSC) on metabolic conditions linked to high-fat diets remains insufficiently studied. This study aimed to evaluate the bioactivity of PSC obtained using ultrasound-water extraction (UW) on metabolic parameters, hepatic function, and inflammation in rats fed a high-fat diet (HFD). Male Wistar rats (5 weeks old, 180–200 g; n = 6 per group) were assigned to normal-diet (ND) or high-fat-diet (HFD) groups, with or without PSC administration. PSC was administered by oral gavage at 400 mg/kg body weight/day for 4 weeks. Compared with the HFD group at week 20, the HFD+PSC group showed 30.44% lower body-weight gain, while LDL-C, AST, ALT, and IL-6 levels were 42.31%, 35.77%, 55.15%, and 41.78% lower. Histopathological examination showed reduced hepatic steatosis and inflammatory alterations following PSC extract administration, with the NAS decreasing from 5.60 ± 0.51 in the HFD group to 2.00 ± 0.32 in the PSC extract administration. The findings indicate that a PSC extract decreased various metabolic, hepatic, and inflammatory changes correlated with HFD. This study supports the potential of PSC extract as a mushrooms-derived functional ingredient to improve metabolic function.